Difference between revisions of "Part:BBa K1699004"

(→‎Characterization)
(→‎Characterization)
 
(3 intermediate revisions by 2 users not shown)
Line 2: Line 2:
 
<partinfo>BBa_K1699004 short</partinfo>
 
<partinfo>BBa_K1699004 short</partinfo>
  
−
gRNA for SaCas9 targeting ubiquitin B under U6 promoter. This gRNA sequence complements 3 different loci in the second exon of human UBB gene, and is under U6 (RNA pol III) promoter.
+
gRNA for SaCas9 targeting human ubiquitin B gene (UBB) under the control of human U6 (RNA polymerase III) promoter. gRNA sequence is complementary to 3 different loci in the second exon of human UBB gene, which is essential for cancer cells (1, 2).
  
  
  
 
===Usage and Biology===
 
===Usage and Biology===
−
usage and biology
+
Guide RNA is a hundred base-long molecule with a unique two dimensional structure which binds Cas9 and guides it to a dsDNA sequence complementary to 21-22 base pairs on the 5' end of the molecule. gRNA scaffold sequence for SaCas9 was used (3). UBB gene was chosen as a model for SaCas9-mediated gene knock-out. UBB is essential for survival of multiple cancer cell types (1, 2).
−
 
+
  
 
===Characterization===
 
===Characterization===
 +
This part was designed as a control construct for two cancer-specific promoter-based design of CRISPR-mediated gene knock-out. In the design, gRNA is ribozyme-flanked (to enable synthesis under RNA polymerase II promoter) and is under control of human survivin promoter.
 +
 +
'''U6-gUBB''': AAV vector for the synthesis of gRNA for SaCas9 targeting human Ubiquitin B gene (abbreviated as gUBB) under the control of human U6 promoter (Fig. 1).
 +
 +
[[Image:U6-gUBB-pAAV_Map.jpg|center|500px|thumb|'''Fig. 1'''. Plasmid map of AAV vector carrying gUBB under the control of human U6 promoter.]]
 +
 +
===References===
 +
1. Downregulation of ubiquitin level via knockdown of polyubiquitin gene Ubb as potential cancer therapeutic intervention. Oh C, Park S, Lee EK, Yoo YJ. Sci Rep. 2013;3:2623. doi: 10.1038/srep02623. http://www.ncbi.nlm.nih.gov/pubmed/24022007
 +
 +
2. The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention. Chen D, Dou QP. Curr Protein Pept Sci. 2010 Sep;11(6):459-70. Review. http://www.ncbi.nlm.nih.gov/pubmed/20491623
 +
 +
3. In vivo genome editing using Staphylococcus aureus Cas9. Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ, Zetsche B, Shalem O, Wu X, Makarova KS, Koonin EV, Sharp PA, Zhang F. Nature. 2015 Apr 9;520(7546):186-91. doi: 10.1038/nature14299. Epub 2015 Apr 1. http://www.ncbi.nlm.nih.gov/pubmed/25830891
  
 
<!-- -->
 
<!-- -->

Latest revision as of 12:24, 13 September 2015

gRNA for SaCas9 targeting human ubiquitin B gene under U6 promoter

gRNA for SaCas9 targeting human ubiquitin B gene (UBB) under the control of human U6 (RNA polymerase III) promoter. gRNA sequence is complementary to 3 different loci in the second exon of human UBB gene, which is essential for cancer cells (1, 2).


Usage and Biology

Guide RNA is a hundred base-long molecule with a unique two dimensional structure which binds Cas9 and guides it to a dsDNA sequence complementary to 21-22 base pairs on the 5' end of the molecule. gRNA scaffold sequence for SaCas9 was used (3). UBB gene was chosen as a model for SaCas9-mediated gene knock-out. UBB is essential for survival of multiple cancer cell types (1, 2).

Characterization

This part was designed as a control construct for two cancer-specific promoter-based design of CRISPR-mediated gene knock-out. In the design, gRNA is ribozyme-flanked (to enable synthesis under RNA polymerase II promoter) and is under control of human survivin promoter.

U6-gUBB: AAV vector for the synthesis of gRNA for SaCas9 targeting human Ubiquitin B gene (abbreviated as gUBB) under the control of human U6 promoter (Fig. 1).

Error creating thumbnail: Invalid thumbnail parameters
Fig. 1. Plasmid map of AAV vector carrying gUBB under the control of human U6 promoter.

References

1. Downregulation of ubiquitin level via knockdown of polyubiquitin gene Ubb as potential cancer therapeutic intervention. Oh C, Park S, Lee EK, Yoo YJ. Sci Rep. 2013;3:2623. doi: 10.1038/srep02623. http://www.ncbi.nlm.nih.gov/pubmed/24022007

2. The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention. Chen D, Dou QP. Curr Protein Pept Sci. 2010 Sep;11(6):459-70. Review. http://www.ncbi.nlm.nih.gov/pubmed/20491623

3. In vivo genome editing using Staphylococcus aureus Cas9. Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ, Zetsche B, Shalem O, Wu X, Makarova KS, Koonin EV, Sharp PA, Zhang F. Nature. 2015 Apr 9;520(7546):186-91. doi: 10.1038/nature14299. Epub 2015 Apr 1. http://www.ncbi.nlm.nih.gov/pubmed/25830891

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal AgeI site found at 250
  • 1000
    COMPATIBLE WITH RFC[1000]